Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume 22, Issue 5, July 1998, Pages 723-739
Full length original paper clinical studyReversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients
References (32)
- et al.
Determination of clozapine and desmethylclozapine in human using plasma by high-performance liquid chromatography with ultraviolet detection
J Chromat Biomed Appl.
(1993) - et al.
Fluvoxamine increases the clozapine serum levels significantly
Eur J Neuropsychopharmacol
(1996) - et al.
Determination of clozapine and its major metabolites in human serum using automated solid phase extraction and subsequent isocratic high performance liquid chromatography
J Chromat Biomed Appl
(1992) - et al.
Tissue concentrations of clozapine and its metabolites in the rat
Neuropsychopharmacol
(1993) - et al.
Clozapine disposition covaries with CYP 1A2 activity determined by caffeine test
Br J Clin Pharmacol
(1994) - et al.
Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection
Psychopharmacol
(1988) - et al.
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate
Am J Psychiat
(1994) - et al.
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
Am J Psychiat
(1996) - et al.
Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia
Therapeutic Drug Monitor
(1997) - et al.
The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: The reversible metabolism of methylprednisolone and methylprednisone in rats
J Pharmacokinet Biopharm.
(1986)
Elucidation of individual cytochrome P450 isoenzymes involved in the metabolism of clozapine
7th North American ISSX Mtg, San Diego, CA
(1996)
The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P4502D6
J Pharmacol Exp Ther
(1992)
Applied pharmacokinetics of haloperidol in man
Curr Ther Res
(1977)
Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age
Psychopharmacol
(1989)
Influence of patient-related variables on clozapine plasma levels
Am J Psychiat
(1990)
Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients
Psychopharmacol
(1990)
Cited by (81)
Clozapine metabolism and cardiotoxicity: A prospective longitudinal study
2024, International Journal of CardiologyThe use of chemogenetic actuator ligands in nonhuman primate DREADDs-fMRI
2023, Current Research in NeurobiologyEvidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders
2021, Molecular TherapyCitation Excerpt :While clozapine-N-oxide (CNO) was initially proposed as an ideal DREADD-activating drug with high affinity and selectivity for DREADD receptors and has been extensively used in rodent studies (for review, see Wess et al.35), recent pharmacokinetic evidence suggests that CNO has poor brain penetrance.36,37 Additionally, studies in rodents, humans, and NHPs demonstrate that CNO can be back-metabolized into clozapine.36–41 Because clozapine has high brain penetrance36,42 and can activate DREADDs at low doses,20,36 it has been suggested that the effects of CNO are mediated, at least in part, by clozapine.36,37
Copyright © 1998 Published by Elsevier Inc.